Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 374Neoplasms 325Neoplasm Metastasis 289Leukemia, Myeloid, Acute 282Breast Neoplasms 276Colorectal Neoplasms 238Melanoma 196Ovarian Neoplasms 192Recurrence 185Multiple Myeloma 180Prostatic Neoplasms 157Pancreatic Neoplasms 156Lung Neoplasms 156Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 145Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 117Carcinoma, Renal Cell 111Stomach Neoplasms 110Advanced Solid Tumors 108Glioma 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Brain Neoplasms 104Lymphoma 103Lymphoma, Large B-Cell, Diffuse 102Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 90

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × ALK Positive Non-small Cell Lung Cancer × 1 year × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡